Disease characteristics, comorbidities, treatment patterns and quality of life impact in children <12 years old with atopic dermatitis: Interim results from the PEDISTAD Real-World Registry
Por:
Paller AS, Guttman-Yassky E, Schuttelaar MLA, Irvine AD, Baselga E, Kataoka Y, Antila M, de Bruin-Weller M, Marcoux D, Abramova A, Rizova E, Liu C and Zhang A
Publicada:
1 nov 2022
Ahead of Print:
1 oct 2022
Categoría:
Dermatology
Resumen:
Filiaciones:
Paller AS:
Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Guttman-Yassky E:
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Schuttelaar MLA:
Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Irvine AD:
Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland
Dermatology, Children's Health Ireland, Crumlin, Ireland
National Children's Research Centre, Dublin, Ireland
Baselga E:
Department of Dermatology, Hospital Sant Joan de Déu, Barcelona, Spain
Kataoka Y:
Department of Dermatology, Osaka Habikino Medical Center, Habikino City, Osaka, Japan
Antila M:
Clínica de Alergía, Sorocaba, Sao Paulo, Brazil
de Bruin-Weller M:
National expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, Netherlands
Marcoux D:
Division of Dermatology, Department of Pediatrics, University of Montreal and CHU Sainte-Justine University Hospital Center, Montreal, QC, Canada
Abramova A:
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Rizova E:
Sanofi Genzyme, Cambridge, MAs, USA
Liu C:
Sanofi, Bridgewater, New Jersey, NJ, USA
Zhang A:
Sanofi Genzyme, Cambridge, MAs, USA
Green Submitted, hybrid
|